Cargando…
Total synthesis of remdesivir()
Remdesivir, the first drug approved by the FDA to treat COVID-19, is in high demand for patients infected with the SARS-CoV-2 virus. Herein, we report a facile approach minimizing the protecting group manipulations to afford remdesivir in good overall yield.
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656175/ https://www.ncbi.nlm.nih.gov/pubmed/34908617 http://dx.doi.org/10.1016/j.tetlet.2021.153590 |
| _version_ | 1784612229670240256 |
|---|---|
| author | Kumar Palli, Kishore Ghosh, Palash Krishna Avula, Shiva Sridhara Shanmukha Rao, B. Patil, Amol D. Ghosh, Subhash Sudhakar, Gangarajula Raji Reddy, Chada Mainkar, Prathama S. Chandrasekhar, Srivari |
| author_facet | Kumar Palli, Kishore Ghosh, Palash Krishna Avula, Shiva Sridhara Shanmukha Rao, B. Patil, Amol D. Ghosh, Subhash Sudhakar, Gangarajula Raji Reddy, Chada Mainkar, Prathama S. Chandrasekhar, Srivari |
| author_sort | Kumar Palli, Kishore |
| collection | PubMed |
| description | Remdesivir, the first drug approved by the FDA to treat COVID-19, is in high demand for patients infected with the SARS-CoV-2 virus. Herein, we report a facile approach minimizing the protecting group manipulations to afford remdesivir in good overall yield. |
| format | Online Article Text |
| id | pubmed-8656175 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86561752021-12-09 Total synthesis of remdesivir() Kumar Palli, Kishore Ghosh, Palash Krishna Avula, Shiva Sridhara Shanmukha Rao, B. Patil, Amol D. Ghosh, Subhash Sudhakar, Gangarajula Raji Reddy, Chada Mainkar, Prathama S. Chandrasekhar, Srivari Tetrahedron Lett Article Remdesivir, the first drug approved by the FDA to treat COVID-19, is in high demand for patients infected with the SARS-CoV-2 virus. Herein, we report a facile approach minimizing the protecting group manipulations to afford remdesivir in good overall yield. Elsevier Ltd. 2022-01-05 2021-12-09 /pmc/articles/PMC8656175/ /pubmed/34908617 http://dx.doi.org/10.1016/j.tetlet.2021.153590 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Kumar Palli, Kishore Ghosh, Palash Krishna Avula, Shiva Sridhara Shanmukha Rao, B. Patil, Amol D. Ghosh, Subhash Sudhakar, Gangarajula Raji Reddy, Chada Mainkar, Prathama S. Chandrasekhar, Srivari Total synthesis of remdesivir() |
| title | Total synthesis of remdesivir() |
| title_full | Total synthesis of remdesivir() |
| title_fullStr | Total synthesis of remdesivir() |
| title_full_unstemmed | Total synthesis of remdesivir() |
| title_short | Total synthesis of remdesivir() |
| title_sort | total synthesis of remdesivir() |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656175/ https://www.ncbi.nlm.nih.gov/pubmed/34908617 http://dx.doi.org/10.1016/j.tetlet.2021.153590 |
| work_keys_str_mv | AT kumarpallikishore totalsynthesisofremdesivir AT ghoshpalash totalsynthesisofremdesivir AT krishnaavulashiva totalsynthesisofremdesivir AT sridharashanmukharaob totalsynthesisofremdesivir AT patilamold totalsynthesisofremdesivir AT ghoshsubhash totalsynthesisofremdesivir AT sudhakargangarajula totalsynthesisofremdesivir AT rajireddychada totalsynthesisofremdesivir AT mainkarprathamas totalsynthesisofremdesivir AT chandrasekharsrivari totalsynthesisofremdesivir |